DNA Repair Drugs Global Market Report 2024

The dna repair drugs market size has grown exponentially in recent years. It will grow from $8.93 billion in 2023 to $10.89 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth in the historical period can be ascribed to an enhanced comprehension of DNA repair mechanisms, advancements in cancer research, changes in the regulatory landscape for pharmaceuticals, a higher incidence of genetic disorders, and the expansion of personalized medicine.

The dna repair drugs market size is expected to see exponential growth in the next few years. It will grow to $22.72 billion in 2028 at a compound annual growth rate (CAGR) of 20.2%. The anticipated growth in the forecast period can be attributed to the advancement of targeted therapies for DNA repair, an increased emphasis on precision medicine, the rise in the aging population, and augmented funding for the development of DNA repair drugs. Noteworthy trends expected in the forecast period include the incorporation of artificial intelligence in drug discovery for DNA repair, the creation of combination therapies targeting DNA repair pathways, a focus on gene editing technologies, the establishment of personalized treatment regimens based on DNA repair profiles, and a surge in clinical trials for DNA repair drugs.

The anticipated growth of the DNA repair drug market is expected to be driven by the increasing prevalence of cancer. Cancer, a disease characterized by the uncontrolled proliferation of abnormal cells, is influenced by factors such as smoking, radiation, carcinogens, obesity, and genetic mutations. The prevention of cancer involves disrupting DNA repair mechanisms, leading to the cessation of cancerous cell replication and inducing cell death. For example, the American Cancer Society Inc. projects that in 2023, there will be an increase in the number of new cancer cases diagnosed in the US compared to 2020, reaching 1.9 million. Thus, the rising prevalence of cancer is a key factor propelling the growth of the DNA repair drug market.

The growing demand for personalized medicine is expected to contribute to the expansion of the DNA repair drug market. Personalized medicine, an innovative healthcare approach considering individual genetic, environmental, and lifestyle variations, relies on DNA repair drugs for tailored treatments based on patients' specific genetic profiles. These drugs are integral in cancer treatment, biomarker identification, and minimizing adverse effects in the realm of personalized medicine. According to The Personalized Medicine Coalition, personalized medicines accounted for 35% of newly approved new molecular entities (NMEs) in 2021. Hence, the increasing demand for personalized medicine is a significant driver for the growth of the DNA repair drug market.


DNA repair drug market is witnessing a prominent trend of product innovation. Leading companies in the DNA repair drugs sector are actively engaged in developing groundbreaking products to fortify their market presence. A notable example is AstraZeneca PLC, a UK-based biopharmaceutical company, which secured approval in June 2023 for Lynparza plus abiraterone in the United States. This approval is specifically for treating BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib), the first-of-its-kind PARP inhibitor, represents a breakthrough as the initial targeted drug capable of blocking the DNA damage response (DDR) in cells or tumors without homologous recombination repair (HRR).

Major players in the DNA repair drug market are directing their efforts toward the development of innovative solutions, such as oral poly ADP-ribose polymerase (PARP) inhibitors. These medications, administered orally, are designed to target the PARP enzyme's activity. Pfizer Inc., a prominent US-based pharmaceutical company, exemplifies this trend with the FDA approval announcement in June 2023 for 'TALZENNA' (talazoparib). TALZENNA, the first and only PARP inhibitor approved for use alongside the established standard of care, XTANDI, is intended for adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) exhibiting mutations in homologous recombination repair (HRR) genes. By inhibiting PARP enzyme activity and capturing PARP at the DNA damage site, TALZENNA hinders cancer cell growth and induces cell death.

In November 2022, Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company specializing in rare disorder therapies, acquired LogicBio Therapeutics Inc. for an undisclosed sum. This acquisition positions Alexion to expedite its foray into genomic therapeutics, leveraging LogicBio's distinctive technology, seasoned rare disease R&D team, and expertise in pre-clinical development. LogicBio Therapeutics Inc. is a clinical-stage genetic medicine company with a focus on gene delivery and gene editing platforms to address rare diseases.

Major companies operating in the dna repair drugs market report are Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., BioMarin Pharmaceutical Inc., Genentech Inc., Clovis Oncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., Intellia Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA, CRISPR Therapeutics AG.

North America was the largest region in the DNA repair drugs market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the dna repair drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna repair drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of DNA repair drugs include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib, for instance, is a medication prescribed for adults dealing with specific forms of prostate cancer, pancreatic cancer, breast cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, either as a standalone treatment or in combination with other medications. These drugs are made available through hospital pharmacies, retail pharmacies, and other distribution channels for the treatment of conditions such as ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and more.

The DNA repair drugs research report is one of a series of new reports that provides DNA repair drugs market statistics, including the DNA repair drugs industry's global market size, regional shares, competitors with DNA repair drugs market share, detailed DNA repair drugs market segments, market trends and opportunities, and any further data you may need to thrive in the DNA repair drugs industry. This DNA repair drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The DNA repair drugs market consists of sales of veliparib, methyl methane sulfonate, mitomycin C, and cisplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.